Opendata, web and dolomites

MMpredict SIGNED

Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectiveness in patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MMpredict project word cloud

Explore the words cloud of the MMpredict project. It provides you a very rough idea of what is the project "MMpredict" about.

strategy    treatment    diagnostic    heterogeneity    centres    intended    survival       mm    outcome    patient    renowned    microarray    economic    effectiveness    assay    blood    trial    combining    specialised    kols    urgent    prevent    molecular    ivd    organisation    variability    annually    mmprofiler    supports    expertise    sme    prediction    predicts    expanded    life    science    myeloma    unmet    reduce    suitable    outcomes    patients    health    prognosis    gene    gt    consists    cancers    error    expression    respectively    strategies    quality    filed    personalised    renaming    complicates    subtype    registration       commercialise    individual    positioning    previously    predict    clinical    intrinsic    mmpredictor       healthcare    tool    form    deaths    treatments    profiling    advocacy    market    15    cancer    decision    complementary    diagnostics    skylinedx    addendum    reliably    options    tumour    successfully    vitro    multiple    world    medicine   

Project "MMpredict" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.mmh2020.eu/
 Total cost 3˙755˙802 €
 EC max contribution 2˙949˙027 € (79%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
 Code Call H2020-FTIPilot-2015-1
 Funding Scheme IA
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 419˙687.00
2    SKYLINEDX B.V. NL (ROTTERDAM) participant 1˙882˙475.00
3    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 387˙500.00
4    ERASMUS UNIVERSITEIT ROTTERDAM NL (ROTTERDAM) participant 210˙615.00
5    MYELOMA PATIENTS EUROPE AISBL BE (Charleroi) participant 48˙750.00

Map

 Project objective

The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second most common form of blood cancer contributing to 15% of all blood cancers and ~1,5% and 2% of all cancer deaths annually in the EU and US, respectively. Patients show a large variability in treatment response and side effects due to tumour heterogeneity and the patient’s intrinsic characteristics. Therefore, not every treatment will be suitable for each patient, and treatment strategies are often based on trial-and-error. The availability of multiple (>20) treatment options complicates treatment decision-making even more. With the current development of many more promising treatments, there is an urgent unmet clinical need for a diagnostic assay that supports personalised cancer treatment in order to improve patient health outcomes, prevent side effects and reduce healthcare costs. SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test’s clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling. An addendum for new intended use will be filed to the current in vitro diagnostic (IVD) registration, while renaming the test to MMpredictor. The project will also focus on positioning the test as a cost-effective IVD test for personalised medicine, that will increase health outcome and quality of life of patients and reduce healthcare costs. The consortium consists of a life science SME specialised in molecular diagnostics, clinical centres with world renowned KOLs, a leading health economic institute, and a European MM patient advocacy organisation combining all the required complementary expertise to successfully bring the MMpredictor to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MMPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MMPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.)

Innovation Principle (2019)

Developing an Innovation-Friendly Legislative Culture – the Innovation Principle at Work

Read More  

PULSe (2017)

Pervasive Ubiquitous Lightwave SEnsor

Read More  

MedEye (2017)

Accelerated market launch of MedEye, a plug-and-play medication safety solution

Read More